Categories AlphaGraphs, Earnings, Health Care

Earnings: Teva Pharma shrinks Q4 losses, but revenue falls

Teva Pharma (TEVA) posted its fourth-quarter 2018 before the opening bell on Feb. 13. The generic drugmaker saw revenue slip 16% to $4.56 billion in the quarter, while net attributable loss shrunk to $2.94 billion or $2.85 per diluted share vs. $11.6 billion or $11.41-a-share in losses a year ago. Non-GAAP profit slipped to $543 million or $0.53 per diluted share, down from last year’s $949 million or $0.93 per share.

The Street expected Teva to post a loss of 53 cents a share on estimated revenue of $4.54 billion. Earnings were more in line with the consensus, but revenue surpassed it by a bit.

Teva Pharmaceuticals fourth quarter earnings infographic

Net non-GAAP adjustments for Teva in the fourth quarter were $3.48billion. Non-GAAP net income and non-GAAP EPS for the fourth quarter were adjusted to exclude a goodwill impairment of $2,73 billion related to International Markets, a $990-million impairment related to the acquisition of Actavis Generics, and other effects and expenses.

 

LOOKING TO 2019

For 2019, Teva sees revenues of $17.0-17.4 billion generating non-GAAP operating income of $3.8-4.2 billion and non-GAAP EPS of $2.20-2.50.

For the coming year, Teva expects continued generic erosion in global COPAXONE sales, touting it to be at about $1.5 billion.

However, the drugmaker expects new launches to offset slight volume decline toNorth America Generics. For International generics, Teva expects an adverse impact in Japan due to NHI price revision and LLP erosion.

 

 

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

2 thoughts on “Earnings: Teva Pharma shrinks Q4 losses, but revenue falls

Leave a Reply

Your email address will not be published. Required fields are marked *

Add Comment
Loading...

Cancel
Viewing Highlight
Loading...
Highlight
Close
Top